Q8BG30
Gene name |
Nelfa (Whsc2, Whsc2h) |
Protein name |
Negative elongation factor A |
Names |
NELF-A, Wolf-Hirschhorn syndrome candidate 2 homolog, mWHSC2 |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:24116 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q8BG30
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q8BG30-F1 | Predicted | AlphaFoldDB |
26 variants for Q8BG30
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs3388755373 | 2 | A>T | No | EVA | |
| rs3388755309 | 24 | W>* | No | EVA | |
| rs3388747428 | 24 | W>R | No | EVA | |
| rs3388751188 | 28 | S>I | No | EVA | |
| rs3388755741 | 44 | C>* | No | EVA | |
| rs3388737989 | 64 | P>T | No | EVA | |
| rs3395396562 | 69 | D>H | No | EVA | |
| rs3388747463 | 80 | Q>R | No | EVA | |
| rs3388749850 | 114 | N>I | No | EVA | |
| rs3388747817 | 123 | E>D | No | EVA | |
| rs3388755701 | 124 | L>H | No | EVA | |
| rs3388751217 | 129 | S>N | No | EVA | |
| rs3388747424 | 145 | N>S | No | EVA | |
| rs3388747435 | 180 | Q>* | No | EVA | |
| rs3388740614 | 300 | Y>F | No | EVA | |
| rs3388752250 | 310 | L>H | No | EVA | |
| rs3388755792 | 318 | T>I | No | EVA | |
| rs3388761020 | 329 | P>T | No | EVA | |
| rs3388751244 | 336 | S>F | No | EVA | |
| rs3388747443 | 339 | P>S | No | EVA | |
| rs3388751219 | 372 | Q>H | No | EVA | |
| rs3388752264 | 400 | P>L | No | EVA | |
| rs3388754968 | 437 | R>G | No | EVA | |
| rs3388744668 | 452 | K>E | No | EVA | |
| rs3388755780 | 470 | E>K | No | EVA | |
| rs3388747446 | 502 | M>I | No | EVA |
No associated diseases with Q8BG30
1 regional properties for Q8BG30
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | Hepatitis delta antigen (HDAg) domain | 89 - 248 | IPR037517 |
5 GO annotations of cellular component
| Name | Definition |
|---|---|
| cytosol | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. |
| NELF complex | A complex of five proteins, designated NELF-A, -B, -C, -D, and -E in human, that can physically associate with RNP polymerase II to induce transcriptional pausing. |
| nuclear body | Extra-nucleolar nuclear domains usually visualized by confocal microscopy and fluorescent antibodies to specific proteins. |
| nucleoplasm | That part of the nuclear content other than the chromosomes or the nucleolus. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
2 GO annotations of molecular function
| Name | Definition |
|---|---|
| chromatin binding | Binding to chromatin, the network of fibers of DNA, protein, and sometimes RNA, that make up the chromosomes of the eukaryotic nucleus during interphase. |
| molecular adaptor activity | The binding activity of a molecule that brings together two or more molecules through a selective, non-covalent, often stoichiometric interaction, permitting those molecules to function in a coordinated way. |
3 GO annotations of biological process
| Name | Definition |
|---|---|
| negative regulation of transcription elongation by RNA polymerase II | Any process that stops, prevents, or reduces the frequency, rate or extent of transcription elongation, the extension of an RNA molecule after transcription initiation and promoter clearance by the addition of ribonucleotides, catalyzed by RNA polymerase II. |
| positive regulation of histone H3-K4 methylation | Any process that activates or increases the frequency, rate or extent of the covalent addition of a methyl group to the lysine at position 4 of histone H3. |
| positive regulation of transcription by RNA polymerase II | Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter. |
1 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| Q9H3P2 | NELFA | Negative elongation factor A | Homo sapiens (Human) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MASMRESDTG | LWLHNKLGAT | DELWAPPSIA | SLLTAAVIDN | IRLCFHRLSS | AVKLKLLLGT |
| 70 | 80 | 90 | 100 | 110 | 120 |
| LHLPRRTVDE | MKAALMDIIQ | LATLDSDPWV | LMVADILKSF | PDTGSLNLDL | EEQNPNVQDI |
| 130 | 140 | 150 | 160 | 170 | 180 |
| LGELREKVSE | CEASAMLPLE | CQYLNKNALT | TLAGPLTPPV | KHFQLKRKPK | SATLRAELLQ |
| 190 | 200 | 210 | 220 | 230 | 240 |
| KSTETAQQLK | RSAGVPFHAK | GRGLLRKMDT | TTPLKGIPKQ | APFRSPTTPS | VFSPSGNRTP |
| 250 | 260 | 270 | 280 | 290 | 300 |
| IPPSRTPLQK | ERGVKLLDIS | ELNTVGAGRE | AKRRRKTLDT | EVVEKPTKEE | TVVENATPDY |
| 310 | 320 | 330 | 340 | 350 | 360 |
| AAGLVSTQKL | GSLNSEPTLP | STSYLPSTPS | VVPASSYIPS | SETPPAPPSR | EASRPPEEPS |
| 370 | 380 | 390 | 400 | 410 | 420 |
| APSPTLPTQF | KQRAPMYNSG | LSPATPAPAA | PTSPLTPTTP | PAVTPTAQTP | PVAMVAPQTQ |
| 430 | 440 | 450 | 460 | 470 | 480 |
| APAPVQQQPK | KNLSLTREQM | FAAQEMFKTA | NKVTRPEKAL | ILGFMAGSRE | NPCPEQGDVI |
| 490 | 500 | 510 | 520 | ||
| QIKLSEHTED | LPKADGQGST | TMLVDTVFEM | NYATGQWTRF | KKYKPMTNVS |